Your session is about to expire
Latuda vs Vraylar
Introduction
For patients diagnosed with bipolar disorder or schizophrenia, certain medications can help manage symptoms by altering levels of neurotransmitters in the brain. Latuda (lurasidone) and Vraylar (cariprazine) are two such drugs that are often prescribed. Both these antipsychotic medicines impact different neurotransmitters but have been shown to help stabilize mood and reduce psychotic symptoms. Latuda is thought to work by blocking dopamine D2 receptors, serotonin 5-HT2A receptors, and serotonin 7 receptors in the brain while enhancing activity at other serotonin receptors (5-HT1A). On the other hand, Vraylar acts as a partial agonist at dopamine D2 and D3 receptors and at certain types of serotonin receptor (5-HT1A), but blocks another type of serotonin receptor (5-HT2A).
Latuda vs Vraylar Side By Side
| Attribute | Latuda | Vraylar |
|---|---|---|
| Brand Name | Latuda | Vraylar |
| Contraindications | Should not be taken with CYP3A4 inhibitors or inducers | Should not be taken with CYP3A4 inhibitors or inducers |
| Cost | $1300 for 30 tablets of 40 mg | $1100 for 30 capsules of 3 mg |
| Generic Name | Lurasidone | Cariprazine |
| Most Serious Side Effect | Thoughts about suicide or self-harm, severe skin reactions, visual disturbances, cardiovascular symptoms, neurological issues | Allergic reactions, skin reactions, unusual shifts in mood or behavior, new or worsening depression, seizures, vision changes, heart issues, symptoms of a manic episode |
| Severe Drug Interactions | Interactions with CYP3A4 inhibitors or inducers | Interactions with CYP3A4 inhibitors or inducers |
| Typical Dose | 20–120 mg/day, with an initial dosage of 40 mg/day for schizophrenia | 1.5 mg/day for bipolar disorder and schizophrenia, up to 6 mg/day |
What is Latuda?
Lurasidone (the generic name for Latuda) is a novel antipsychotic medication of the atypical class, which was a significant advancement over the first generation of antipsychotics known as typical antipsychotics. Lurasidone was approved by the FDA in 2010. It works primarily by blocking dopamine and serotonin receptors in the brain, effectively altering their activity levels. This drug is typically prescribed for schizophrenia and bipolar depression treatment. On one hand, Vraylar (Cariprazine) is another atypical antipsychotic that has been approved for managing manic or mixed episodes linked to bipolar I disorder and for treating schizophrenia. Similar to Latuda, it alters dopamine and serotonin activity but does so with higher selectivity for certain receptor types, which results in different effects and side effect profiles between these two medications.
What conditions is Latuda approved to treat?
Latuda is approved for the treatment of different mental health disorders, including:
- Schizophrenia in adults and adolescents aged 13 to 17 years old
- Bipolar depression (also known as manic-depressive illness) both as a standalone medication and when used alongside lithium or valproate.
How does Latuda help with these illnesses?
Latuda, or lurasidone, helps to manage symptoms of schizophrenia and bipolar depression by balancing the levels of serotonin and dopamine in the brain. These are neurotransmitters that act as messengers between the brain cells and play crucial roles in mood regulation among other functions. Lurasidone works as an antagonist at both serotonin 5-HT2A receptors and dopamine D2 receptors; this means it blocks these receptors from being activated, which can help reduce hallucinations, delusions, thought disorders or mood swings often associated with these conditions. Similarly, Vraylar (cariprazine) also balances serotonin and dopamine levels but has a unique mechanism of action as it acts as a partial agonist at both types of receptors meaning that it can either stimulate or block their activity depending on their current state. Therefore, while they have some similarities in their effects on neurotransmitter systems, the specific mechanisms through which Latuda and Vraylar work differ slightly.
What is Vraylar?
Vraylar, also known by its generic name cariprazine, is a dopamine D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist that has been approved by the FDA. This means it can increase levels of these neurotransmitters in certain areas of the brain by reducing their reabsorption. Vraylar was first approved for use in treating bipolar disorder and schizophrenia in adults by the FDA in 2015.
As Vraylar is not a typical antipsychotic or mood stabilizer, it does not fully antagonize any particular neurotransmitter system. Its unique mechanism allows it to reduce symptoms associated with both mania and depression experienced during bipolar episodes without causing significant sedation or weight gain - common side effects seen with other medications such as Latuda (lurasidone). The specific impact on dopamine and serotonin receptors may be particularly beneficial for patients who do not respond well to more "typical" treatments for bipolar disorder or schizophrenia.
What conditions is Vraylar approved to treat?
Vraylar is a medication approved by the FDA for managing:
- Schizophrenia, a chronic and severe mental disorder that affects how a person thinks, feels and behaves.
- Bipolar I Disorder, an illness characterized by significant shifts in mood, energy and activity levels that can significantly impact day-to-day life. The approval includes manic or mixed episodes in adults.
How does Vraylar help with these illnesses?
Dopamine is a neurotransmitter with multiple roles in the body, impacting mood, attention, memory, and regulates both pleasure and reward. Imbalances in dopamine levels have been linked to various psychiatric disorders including schizophrenia and bipolar disorder. Vraylar works by balancing the levels of dopamine available in the brain which can help alleviate some symptoms associated with these conditions such as hallucinations or mood swings. Its action on other neurotransmitters like serotonin may also play significant roles in its effectiveness as an antipsychotic drug. Since it does not significantly affect norepinephrine levels, it is sometimes prescribed when a patient does not respond well to other atypical antipsychotics (such as Latuda), or may be combined with them.
How effective are both Latuda and Vraylar?
Both lurasidone (Latuda) and cariprazine (Vraylar) have proven to be effective in treating patients with schizophrenia, bipolar disorder, and major depressive disorder. Lurasidone was initially approved by the FDA in 2010 followed by cariprazine in 2015. As they act on different neurotransmitters - dopamine, serotonin, and glutamate receptors - they may be prescribed under varying circumstances.
The effectiveness of lurasidone and cariprazine has been shown through numerous double-blind clinical trials. For instance, a trial conducted on schizophrenic patients showed that both drugs exhibited similar efficacy in managing symptoms as well as promising safety profiles. None of the various metrics studied to measure efficacy differed significantly between those receiving lurasidone or cariprazine.
A systematic review from 2021 indicated that Latuda is effective at alleviating symptoms of depression associated with bipolar disorder within the first week of treatment. It also has a favorable side-effect profile compared to other antipsychotics used for this indication, being less likely than many others to cause weight gain or metabolic disturbances.
On the other hand, Vraylar was found to be more effective than placebo at preventing relapse into manic or mixed episodes among individuals with bipolar I disorder according to a meta-analysis published in 2019. Although it's often considered an alternative option when first-line treatments are not successful or suitable due its unique pharmacology and side effect profile including potential for restlessness or movement disorders.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Latuda typically prescribed?
Oral dosages of Latuda range from 20–120 mg/day, but studies have shown that an initial dosage of 40 mg/day is suitable for treating schizophrenia in most individuals. Adolescents with bipolar depression may be started on 20 mg/day. In either population, the dosage can be adjusted after a few weeks if there is no response. The maximum daily dosage that should not be exceeded is 160 mg.
On the other hand, Vraylar has a recommended dose range of 1.5-6mg per day for both schizophrenia and bipolar disorder. An effective starting dose can often be as low as 1.5mg per day; however, adjustments may need to occur based on patient response or tolerability issues over time. It's important to remember never to exceed the maximum recommended daily dose without consulting your healthcare professional.
At what dose is Vraylar typically prescribed?
Treatment with Vraylar typically begins at a dosage of 1.5 mg/day for bipolar disorder and schizophrenia, and 1.5-3 mg/day for depressive episodes associated with bipolar I disorder. The dose can then be increased to a maximum of 6 mg/day, depending on the patient's response to treatment and tolerance level. For patients not responding adequately at lower doses, it may take up to one or two weeks for the full therapeutic effects to manifest since Vraylar has a long half-life in the body.
Remember that each individual's response can vary significantly based on their unique genetic makeup, metabolism rate, concurrent medications taken, as well as other factors like diet and lifestyle habits. Always consult your healthcare provider before making any changes in medication regime.
What are the most common side effects for Latuda?
Common side effects of Latuda include:
- Anxiety and agitation
- Insomnia or sleepiness/drowsiness
- Restlessness (akathisia)
- Nausea, vomiting or indigestion
- Weight gain
- Dry mouth
- Decreased libido (sex drive)
- Difficulty with movement, shuffling walk, stiffness or muscle spasms
While Vraylar may cause:
- Tardive dyskinesia (involuntary movements that can be permanent)
- Dizziness
- Inner sense of restlessness/need to move (akathisia)
- Indigestion/Upset stomach
- Sleep problems such as drowsiness/somnolence
- Tremor
- Unusual changes in behavior/mood
These side effects are not exhaustive. It's important to discuss any concerns about medication side effects with your healthcare provider.
Are there any potential serious side effects for Latuda?
While Vraylar and Latuda are both atypical antipsychotics used to treat bipolar disorder and schizophrenia, they do have different side effect profiles. In rare cases, these can include:
- Thoughts about suicide or self-harm
- Signs of allergic reaction such as hives, difficult breathing, swelling in your face or throat
- Severe skin reactions: fever, sore throat, burning eyes, skin pain or a red/purple skin rash that might blister and peel
- Visual disturbances like blurred vision or seeing halos around lights; eye pain/swelling
- Cardiovascular symptoms: fast/irregular heartbeats/fluttering in the chest; shortness of breath/dizziness (feeling faint)
- Neurological issues: severe muscle rigidity/stiffness; high fever/sweating/confusion/fast or uneven heartbeats/tremors/fainting spells.
If you experience any symptoms associated with low sodium levels - headache/confusion/slurred speech/severe weakness/vomiting/loss of coordination/unsteady gait - seek medical help immediately.
These medications can also cause serotonin syndrome - a potentially life-threatening condition characterized by agitation/hallucinations/fever/sweating/shivering/fast heart rate/muscle stiffness/twitching/loss of coordination/nausea/vomiting/diarrhea. If suspected, discontinue use and get emergency treatment right away.
What are the most common side effects for Vraylar?
Vraylar, compared to Latuda, comes with its own side effect profile that may include:
- Dry mouth and stuffy nose
- Indigestion or stomach discomfort
- Sleep disturbances such as insomnia
- Feeling restless or anxious
- Rapid heartbeat
- Weight gain instead of weight loss
- Increased urination frequency
- Headache and dizziness
- Muscle stiffness or joint pain
It's important to note that everyone reacts differently to medications so not all individuals will experience these side effects. Always consult your healthcare provider before starting new medications.
Are there any potential serious side effects for Vraylar?
In some instances, Vraylar may cause serious side effects. Symptoms that can be concerning and require immediate medical attention include:
- Signs of an allergic reaction such as hives, difficulty breathing, swelling in your face or throat
- Skin reactions: fever, sore throat, burning eyes, skin pain with a red or purple rash causing blistering and peeling
- Unusual shifts in mood or behavior
- New onset or worsening depression including thoughts of suicide
- Seizures (convulsions)
- Vision changes: blurred vision, eye pain or swelling, seeing halos around lights
- Heart issues: fast heartbeat or irregular heart rhythms
- Symptoms suggestive of a manic episode like racing thoughts increased energy levels beyond the normal range leading to reckless behavior; feelings of extreme happiness followed by irritability; excessive talking; severe sleep problems.
If you experience any such symptoms while using Vraylar you should seek immediate medical assistance. It's important to remember that these are potential side effects and many people use this medication without experiencing severe adverse effects.
Contraindications for Latuda and Vraylar?
Both Latuda and Vraylar, like other antipsychotic medications, may worsen symptoms of depression in some individuals. If you notice your condition deteriorating or experience an increase in suicidal thoughts or behavior, please seek immediate medical attention.
Neither Latuda nor Vraylar should be taken if you are currently taking or have recently discontinued the use of certain types of drugs known as CYP3A4 inhibitors or inducers. Always tell your physician about any medications you're using; these substances can interact with both Latuda and Vraylar leading to potentially dangerous effects. Depending on the specific medication involved, it might require a period ranging from several days to weeks for clearance from your system before starting treatment with either Latuda or Vraylar to avoid possible drug interactions.
How much do Latuda and Vraylar cost?
For the brand name versions of these drugs:
- The price for 30 tablets of Latuda (40 mg) averages around $1300, which works out to approximately $43/day.
- The price for Vraylar (3 mg), on the other hand, is about $1100 for a 30 capsule supply, or roughly $36/day.
This suggests that if you are taking comparable doses of each medication, then brand-name Vraylar is less expensive than Latuda on a per-day treatment basis. However, it's important to remember that cost should not be your primary consideration when deciding which drug is best suited to your needs.
As far as generic versions go:
Currently there are no generic versions available in the United States for either Latuda (lurasidone) or Vraylar (cariprazine). This lack of competition contributes significantly to their high prices. It's also worth noting that while both medications treat mental/mood disorders such as bipolar disorder and schizophrenia, they do so in different ways and come with differing side effect profiles — another key factor when considering one over the other.
Popularity of Latuda and Vraylar
Lurasidone, also known by its brand name Latuda, was estimated to have been prescribed to approximately 1.2 million people in the US in 2020. Lurasidone is an atypical antipsychotic primarily used for treating schizophrenia and bipolar depression and accounted for around 8% of prescriptions within this class. The use of lurasidone has seen a steady increase since its approval by the FDA in 2010.
Cariprazine, which comes under the brand name Vraylar, was prescribed to nearly half a million people in the USA during the same year. It represents about 3% of all atypical antipsychotic prescriptions and is mainly utilized for managing symptoms of schizophrenia and bipolar disorder as well. Similar to lurasidone, cariprazine's prevalence has been on an upward trend since it received FDA approval in 2015.
Conclusion
Both Latuda (lurasidone) and Vraylar (cariprazine) are used in the treatment of schizophrenia and bipolar disorder, with a significant amount of clinical studies and meta-analyses confirming their efficacy over placebo treatments. Sometimes these drugs may be combined, but this is subject to careful consideration by a doctor as they can also interact negatively with each other. Due to differing mechanisms of action - Latuda primarily acts on serotonin and dopamine receptors while Vraylar acts mainly on dopamine D3/D2 receptors - they tend to be prescribed under different circumstances.
Latuda has an additional indication for depressive episodes in bipolar I disorder, whereas Vraylar is also approved for manic or mixed episodes in bipolar I disorder. Both medications require dosage titration meaning that effects might not be noticeable immediately.
The side effect profile between the two drugs is somewhat similar, both being generally well-tolerated; however, weight gain tends to occur less frequently with Latuda compared to other atypical antipsychotics including Vraylar. For both medications, patients must carefully monitor their moods when starting therapy and seek immediate medical help if they notice worsening symptoms or begin having suicidal thoughts or thoughts about self-harm.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Loebel, A., & Citrome, L. (2015, October). Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. BJPsych Bulletin. Royal College of Psychiatrists.http://doi.org/10.1192/pb.bp.114.048793
- Sanford, M., & Dhillon, S. (2015, February 20). Lurasidone: A Review of Its Use in Adult Patients with Bipolar I Depression. CNS Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40263-015-0234-2
- Fukuyama, K., Motomura, E., Shiroyama, T., & Okada, M. (2022, April). Impact of 5-HT7 receptor inverse agonism of lurasidone on monoaminergic tripartite synaptic transmission and pathophysiology of lower risk of weight gain. Biomedicine & Pharmacotherapy. Elsevier BV.http://doi.org/10.1016/j.biopha.2022.112750
- McCormack, P. L. (2015, October 28). Cariprazine: First Global Approval. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-015-0494-7
- Phalguni, A., McCool, R., Wood, H., Sanderson, A., Rydevik, G., Franklin, B., & James, D. (2022, July 22). Systematic literature review and network meta-analysis of lurasidone, brexpiprazole and cariprazine for schizophrenia. International Clinical Psychopharmacology. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1097/yic.0000000000000427
- Jaeschke, R. R., Sowa-Kućma, M., Pańczyszyn-Trzewik, P., Misztak, P., Styczeń, K., & Datka, W. (2016, August). Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile. Pharmacological Reports. Springer Science and Business Media LLC.http://doi.org/10.1016/j.pharep.2016.04.002
- Garnock-Jones, K. P. (2017, May 30). Cariprazine: A Review in Schizophrenia. CNS Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40263-017-0442-z